We use cookies to personalise the web experience for you. By using www.helgilibrary.com, you agree to our use of cookies.
Some cookies are also used by Google Analytics, which anonymously tracks visitors and helps us to analyse how users use our website. Read more

Pfizer Czech Republic

Pharmaceutical > Czech Republic > Pfizer Czech Republic
Change Company
Pfizer Czech Republic

Pfizer Czech Republic is a Czech Republic-based subsidiary of the multinational pharmaceutical corporation Pfizer. Pfizer, Inc. develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, diabetology/endocrinology, and neurology. Pfizer's products include the blockbuster drug Lipitor (atorvastatin), used to lower LDL blood cholesterol; Lyrica (pregabalin for neuropathic

Read more »
Pfizer Czech Republic is a Czech Republic-based subsidiary of the multinational pharmaceutical corporation Pfizer. Pfizer, Inc. develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, diabetology/endocrinology, and neurology. Pfizer's products include the blockbuster drug Lipitor (atorvastatin), used to lower LDL blood cholesterol; Lyrica (pregabalin for neuropathic pain/fibromyalgia); Diflucan (fluconazole), an oral antifungal medication; Zithromax (azithromycin), an antibiotic; Viagra (sildenafil, for erectile dysfunction); and Celebrex/Celebra (celecoxib), an anti-inflammatory drug. Pfizer was founded by cousins Charles Pfizer and Charles Erhart in New York City in 1849 as a manufacturer of fine chemicals

Buy all financials of Pfizer Czech Republic

from $199 /month

Buy annual subscriptions for all our products.

summary Unit
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

income statement

Sales CZK mil
Gross Profit CZK mil
EBIT CZK mil
Net Profit CZK mil
ROE %
EBIT Margin %
Net Margin %
Employees
                  6,807 3,118 5,407 4,947 3,122    
                  755 287 502 475 311    
                  303 63.4 170 170 98.2    
                  231 48.1 144 134 75.4    
                  25.2% 4.63% 11.1% 8.21% 5.24%    
                  4.45% 2.03% 3.15% 3.44% 3.15%    
                  3.40% 1.54% 2.67% 2.70% 2.41%    
                  253 203 183 170 121    

balance sheet

                  2,885 2,530 2,812 2,922 1,937    
                  16.5 9.46 7.30 99.1 197    
                  2,866 2,518 2,798 2,818 1,737    
                  1,034 1,043 1,562 1,696 1,180    
                  1,851 1,487 1,249 1,226 757    
                  0.438 0.438 0.000 0.000 0.000    
                  1,835 1,474 1,226 1,212 742    
                  2.16 -1.32 -0.141 -1.65 -0.037    
                  66.1% -8.43% -1.56% -16.8% -0.350%    
... ...             ... 4.09% 0.877% ... ... ... ...  

cash flow

            ... ... ... ... ... ... ... ...    
            ... ... ... ... ... ... ... ...    
            ... ... ... ... ... ... ... ...    
            ... ... ... ... ... ... ... ...    

Download Data
income statement Unit
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

income statement

Sales CZK mil
Cost of Goods & Services CZK mil
Gross Profit CZK mil
Staff Cost CZK mil
Other Cost CZK mil
EBITDA CZK mil
Depreciation CZK mil
EBIT CZK mil
Financing Cost CZK mil
Extraordinary Cost CZK mil
Pre-Tax Profit CZK mil
Tax CZK mil
Minorities CZK mil
Net Profit CZK mil
                  6,807 3,118 5,407 4,947 3,122    
                  6,051 2,831 4,905 4,472 2,811    
                  755 287 502 475 311    
                  389 127 266 271 175    
                  50.5 93.9 63.8 31.9 25.7    
                  316 66.4 173 172 110    
                  13.5 2.99 2.56 2.12 12.2    
                  303 63.4 170 170 98.2    
                  17.5 3.75 0.699 4.58 6.38    
                  -0.007 0.002 -8.21 0.063 0.000    
                  285 59.6 178 165 91.9    
                  53.8 11.6 33.5 31.6 16.5    
                  0.000 0.000 0.000 0.000 0.000    
                  231 48.1 144 134 75.4    

growth rates

...                 4.32% -54.2% 73.4% -8.51% -36.9%    
...                 -17.5% -49.8% 49.5% -8.06% -33.8%    
...                 93.1% -79.0% 160% -0.368% -35.9%    
...                 114% -79.1% 169% -0.115% -42.2%    
...                 132% -79.1% 198% -6.94% -44.5%    
...                 137% -79.2% 200% -7.25% -43.7%    

ratios

                  25.2% 4.63% 11.1% 8.21% 5.24%    
...                 13.9% 4.56% 18.1% 16.1% 7.83%    
                  11.1% 9.20% 9.29% 9.61% 9.96%    
                  4.64% 2.13% 3.20% 3.48% 3.54%    
                  4.45% 2.03% 3.15% 3.44% 3.15%    
                  3.40% 1.54% 2.67% 2.70% 2.41%    
... ...             ... 4.09% 0.877% ... ... ... ...  
                  2.16 -1.32 -0.141 -1.65 -0.037    

Download Data
balance sheet Unit
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

balance sheet

                  16.5 9.46 7.30 99.1 197    
                  16.3 9.44 7.30 5.16 3.21    
                  0.181 0.026 0.000 93.9 194    
                  2,866 2,518 2,798 2,818 1,737    
                  959 933 1,095 813 716    
                  1,305 900 973 733 1,007    
                  172 87.9 24.3 284 4.12    
                  2,885 2,530 2,812 2,922 1,937    
                  1,034 1,043 1,562 1,696 1,180    
                  0.000 0.000 0.000 0.000 0.000    
                  1,851 1,487 1,249 1,226 757    
                  0.438 0.438 0.000 0.000 0.000    
                  0.000 0.000 0.000 0.000 0.000    
                  0.000 0.000 0.000 0.000 0.000    
                  1,835 1,474 1,226 1,212 742    
                  856 0.000 0.000 0.000 0.000    
                  734 1,280 1,039 1,023 616    
                  16.2 12.9 23.3 13.5 15.0    
                  2,885 2,530 2,812 2,922 1,937    

growth rates

...                 -3.91% -12.3% 11.1% 3.91% -33.7%    
...                 28.8% 0.865% 49.8% 8.56% -30.5%    
...                 -703% -113% -72.3% 1,069% -98.5%    
... ... ...       ...   ... ... -100% ... ... ... ... ...

ratios

                  856 0.000 0.000 0.000 0.000    
                  684 -87.9 -24.3 -284 -4.12    
                  1,530 552 1,028 523 1,107    
                  1,546 561 1,035 622 1,304    
                  66.1% -8.43% -1.56% -16.8% -0.350%    
... ...             ... 4.09% 0.877% ... ... ... ...  

Download Data
cash flow Unit
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

cash flow

                  231 48.1 144 134 75.4    
                  13.5 2.99 2.56 2.12 12.2    
...           ... ... ... ... ... ... ... ...    
...           ... ... ... ... ... ... ... ...    
            ... ... ... ... ... ... ... ...    
            ... ... ... ... ... ... ... ...    
            ... ... ... ... ... ... ... ...    
            ... ... ... ... ... ... ... ...    
... ... ... ... ... ... ... ... ... ... ... ... ... ...    
...           ... ... ... ... ... ... ... ...    
            ... ... ... ... ... ... ... ...    
            ... ... ... ... ... ... ... ...    

ratios

                  70.0 105 65.7 54.1 118    
                  57.8 120 81.5 66.3 92.9    
                  44.3 165 77.4 83.5 80.0    
                  83.6 60.5 69.8 36.9 131    
                  245 51.0 147 136 87.5    
            ... ... ... ... ... ... ... ...    

Download Data
other data Unit
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

other data

                  7.86% 1.77% 5.40% 4.67% 3.10%    
                  11.1% 9.20% 9.29% 9.61% 9.96%    
                  253 203 183 170 121    
                  7,241 2,655 6,187 6,218 5,044    
                  128,064 51,930 121,053 132,894 120,395    
                  5.98% 4.14% 5.08% 5.68% 5.78%    
                  18.9% 19.4% 18.9% 19.1% 18.0%    
                  3,372 1,524 2,727 2,528 1,254    
            ... ... ... ... ... ... ... ...    
                  3,436 1,594 2,680 2,418 1,868    
                  50.5% 51.1% 49.6% 48.9% 59.8%    
                  3,395 1,502 2,710 2,524 2,824    
                  3,413 1,616 2,697 2,422 298    

Download Data
Comparison of 9 Companies in Czech Pharmaceutical Companies

This Annual Statistical Dossier offers a comparison of 9 companies from Czech Pharmaceutical Companies from 2000 to 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

The file

Read more »

This Annual Statistical Dossier offers a comparison of 9 companies from Czech Pharmaceutical Companies from 2000 to 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

The file contains data of following companies:

If you are only interested in particular areas of the company's business, you can find and download specific indicators from the company's Corporate Profile, or specific charts from the company's Chart Section.

Download a sample excel file attached to see more details. On purchase, the hidden cells will be unlocked and all available data wll be visible.

Pfizer Czech Republic in Numbers

This Annual Statistical Dossier offers a summary of Pfizer Czech Republic's performance between 2002 and 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

If you are only

Read more »

This Annual Statistical Dossier offers a summary of Pfizer Czech Republic's performance between 2002 and 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

If you are only interested in particular areas of the company's business, you can find and download specific indicators from the company's Corporate Profile, or specific charts from the company's Chart Section.

If you are interested in the company’s quarterly figures, please refer to the company’s Quarterly Statistical Dossier.

Pfizer Czech Republic at a Glance

Pfizer Czech Republic is a Czech Republic-based subsidiary of the multinational pharmaceutical corporation Pfizer. Pfizer, Inc. develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, diabetology/endocrinology, and neurology. Pfizer's products include the blockbuster drug Lipitor (atorvastatin),

Read more »

Pfizer Czech Republic is a Czech Republic-based subsidiary of the multinational pharmaceutical corporation Pfizer. Pfizer, Inc. develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, diabetology/endocrinology, and neurology. Pfizer's products include the blockbuster drug Lipitor (atorvastatin), used to lower LDL blood cholesterol; Lyrica (pregabalin for neuropathic pain/fibromyalgia); Diflucan (fluconazole), an oral antifungal medication; Zithromax (azithromycin), an antibiotic; Viagra (sildenafil, for erectile dysfunction); and Celebrex/Celebra (celecoxib), an anti-inflammatory drug. Pfizer was founded by cousins Charles Pfizer and Charles Erhart in New York City in 1849 as a manufacturer of fine chemicals.

This report offers a summary of the company's performance in 2002-2011. You will find here all the key numbers from the company's balance sheet, income statement and cash flow on the annual, in the local currency as well as in USD

Pfizer Czech Republic in Numbers

Pfizer Czech Republic is a Czech Republic-based subsidiary of the multinational pharmaceutical corporation Pfizer. Pfizer, Inc. develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, diabetology/endocrinology, and neurology. Pfizer's products include the blockbuster drug Lipitor (atorvastatin),

Read more »

Pfizer Czech Republic is a Czech Republic-based subsidiary of the multinational pharmaceutical corporation Pfizer. Pfizer, Inc. develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, diabetology/endocrinology, and neurology. Pfizer's products include the blockbuster drug Lipitor (atorvastatin), used to lower LDL blood cholesterol; Lyrica (pregabalin for neuropathic pain/fibromyalgia); Diflucan (fluconazole), an oral antifungal medication; Zithromax (azithromycin), an antibiotic; Viagra (sildenafil, for erectile dysfunction); and Celebrex/Celebra (celecoxib), an anti-inflammatory drug. Pfizer was founded by cousins Charles Pfizer and Charles Erhart in New York City in 1849 as a manufacturer of fine chemicals.

This excel file offers a summary of the company's performance in 2002-2011. You will find here all the key numbers from the company's balance sheet, income statement and cash flow on the annual, in the local currency as well as in USD

Pfizer Czech Republic made a net profit of CZK CZK 103 mil under revenues of CZK 3,586 mil in 2017, up 39.7% and 10.6%, respectively, when compared to the last year.

This translates into a net margin of 2.86%. Historically, the

Read more »

Pfizer Czech Republic made a net profit of CZK CZK 103 mil under revenues of CZK 3,586 mil in 2017, up 39.7% and 10.6%, respectively, when compared to the last year.

This translates into a net margin of 2.86%. Historically, the firm’s net margin reached an all time high of 7.17% in 2003 and an all time low of -30.0% in 2002. The average net margin in the last five years amounted to 2.58%.

On the operating level, EBITDA margin reached 3.68% and EBIT amounted to 4.36% of sales in 2017.

As far as Pfizer Czech Republic's peers are concerned, Bayer Czech Republic posted net and EBITDA margin of 2.53% and 3.77%, respectively in 2017 and Amgen Czech Republic generated margins of 9.06% and 11.8%.

You can see all the company’s data at Pfizer Czech Republic Profile, or you can download a report on the company in the report section.

Pfizer Czech Republic made a net profit of CZK 103 mil in 2017, up 39.7% when compared to the last year. Total sales reached CZK 3,586 mil, which is up 10.6% when compared to the previous year.

Historically, the company’s

Read more »

Pfizer Czech Republic made a net profit of CZK 103 mil in 2017, up 39.7% when compared to the last year. Total sales reached CZK 3,586 mil, which is up 10.6% when compared to the previous year.

Historically, the company’s net profit reached an all time high of CZK 272 mil in 2008 and an all time low of CZK -29.9 mil in 2005.

In terms of sales, Pfizer Czech Republic reached an all time high of CZK 6,807 mil in 2011 and an all time low of CZK 2,057 mil in 2003.

Pfizer Czech Republic's net profit has grown 16.4% a year on average in the last five years while sales have increased by 2.84% a year since 2012.

The firm generated its shareholders an average return on invested capital of 10.7% in the last five years.

As far as Pfizer Czech Republic's peers are concerned, Bayer Czech Republic posted a net profit and sales of CZK 106 mil and CZK 4,180 mil in 2017 and Amgen Czech Republic generated a net profit of CZK 37.8 mil (with sales of CZK 417 mil).

You can see all the company’s data at Pfizer Czech Republic Profile, or you can download a report on the company in the report section.

Pfizer Czech Republic made a net profit of CZK 103 mil under revenues of CZK 3,586 mil in 2017, up 39.7% and 10.6%, respectively, when compared to the last year. This translates into a net margin of 2.86%.

Historically, the firm’s

Read more »

Pfizer Czech Republic made a net profit of CZK 103 mil under revenues of CZK 3,586 mil in 2017, up 39.7% and 10.6%, respectively, when compared to the last year. This translates into a net margin of 2.86%.

Historically, the firm’s net profit reached an all time high of CZK 272 mil in 2008 and an all time low of CZK -263 mil in 2002. Since 2012, the firm's net profit has increased 113% or 16.4% a year on average.

On the operating level, EBITDA reached CZK 156 mil, up 30.7% when compared to the previous year. Over the last five years, company's EBITDA has grown 18.7% a year on average.

As far as Pfizer Czech Republic's peers are concerned, Bayer Czech Republic posted net and EBITDA margin of 2.53% and 3.77%, respectively in 2017 and Amgen Czech Republic generated margins of 9.06% and 11.8%.

You can see all the company’s data at Pfizer Czech Republic Profile, or you can download a report on the company in the report section.

Pfizer Czech Republic's net debt reached CZK 329 mil and accounted for 24.2% of equity at the end of 2017. The ratio is up 5453% when compared to the previous year.

Historically, the firm’s net debt to equity reached an all

Read more »

Pfizer Czech Republic's net debt reached CZK 329 mil and accounted for 24.2% of equity at the end of 2017. The ratio is up 5453% when compared to the previous year.

Historically, the firm’s net debt to equity reached an all time high of 199% in 2006 and an all time low of -150% in 2004.

When compared to EBITDA, net debt amounted to 2.10x at the end of the year. The ratio reached an all time high of 5.38 in 2005 and an all time low of -1.65 in 2014.

As far as Pfizer Czech Republic's peers are concerned, Bayer Czech Republic posted net debt to equity of 94.4%x and 2.49x when compared to EBITDA at the end of 2017. Amgen Czech Republic ended the year 2017 with a net debt at -0.147%x of equity and -0.006x when compared to its EBITDA while Amgen Czech Republic had net debt at -0.147%x of equity and -0.006x to EBITDA at the end of the year.

You can see all the company’s data at Pfizer Czech Republic Profile, or you can download a report on the company in the report section.

See all charts of the company »
Pfizer CR's net profit rose 39.7% to CZK 103 mil in 2017
Pfizer CR's net profit rose 39.7% to CZK 103 mil in 2017
Pfizer CR's employees rose 51.0% to 219 in 2017
Pfizer CR's Total Cash From Operations fell 2,773% to CZK -700 mil in 2017
Pfizer CR's Capital Expenditures rose 630% to CZK 142 mil in 2017
Pfizer CR's Net Debt/EBITDA rose 4,530% to 2.10 in 2017
Pfizer CR's Cash & Cash Equivalents rose 56.5% to CZK 8.88 mil in 2017
Pfizer CR's ROCE rose 13.7% to 6.11% in 2017
Pfizer CR's Net Margin rose 26.4% to 2.86% in 2017